This should be the first step of multicenter study of CDI in Japan, even if it has quite a few weak points and limitations. Of their results, it is interesting that the use of vancomycin was associated with a decreased risk of mortality. This study might show the actual situation that people in Japanese medical facilities need more education for awareness and understanding for CDI. I think that it might be good to discuss of it. The paper can be compacted. The authors need to refer more appropriate references. It is quite strange that authors did refer no publications documenting CDI in Japan.
Introduction

1.
In this study, the authors did not represent the incidence of CDI in Japanese hospitals. The following sentences should be deleted: In Japan, the Ministry of Health, Welfare, and Labor"s Japan Nosocomial Infection Surveillance program investigates the incidence rates of a variety of drug-resistant bacteria; however, this program does not monitor the incidence rate of C. difficile (http://www.nih-janis.jp/index.asp).
2.
Therefore, CDI epidemiological studies in Japan to date have been based on scattered data from individual medical facilities. >>> References reporting "scattered data from Japan" should be referred. It is strange that no papers about CDI in Japan were referred in this study. 3.
Consequently, the phenomenon of CDI in Japan is not sufficiently understood. Reports of BI/NAP1/027 infections are limited, and conditions in Japan possibly differ from those in Europe and North America. >>> Please give me good reasons why the authors did cite no papers about CDI or typing analysis from Japan. In this study, Clostridium difficile isolates recovered from the 47 facilities were not analyzed, and then the authors could give no data about CDI caused by BI/NAP1/027 or other types in Japan. The sentences might be changed.
Materials and Methods
1.
Definition of CDI is poorly described. Does "C. difficile isolation from stool culture" mean toxigenic culture? Especially in two facilities, only C. difficile culture was used for the laboratory test (Table 1) .
2.
It should be clear that the control group cases were selected regardless of intestinal symptoms such as diarrhea. 3.
The following sentences might be deleted; The study coordinator established independent data management centers within the NHO facilities for data collection. All input data were verified by a designated study data manager. Data from each facility were entered directly into a web-based case report form and subsequently encrypted for security. The data management center was responsible for confirming any missing data and directly inquiring the relevant facilities as necessary. After the end of the study period, the data were finalized and subsequently transferred to the Research Coordinator"s office. 4.
In this study, clinical outcomes of cases within 30 days of CDI development were investigated. How did the authors investigate it? Did the authors make a phone call the all patients who discharged from the facilities without taking any direct informed consent when they were involved in the study?
Results
1.
The following sentences might be deleted; the regional locations of the 47 facilities were as follows: 5 in Hokkaido and Tohoku, 10 in Kanto and Koshinetsu, 2 in Tokai and Hokuriku, 9 in Kinki, 10 in Chugoku and Shikoku, and 11 The findings of this investigation are similar to those reported in previous studies conducted in Europe, North America, and Australia >>> The incidence of CDI differs from those reported form Europe, North America, and Australia. It could be mentioned that this point possibly may have an effect on risk factors or mortality.
3.
Although proton pump inhibitor use was indicated as a risk factor for CDI development in previous studies[9, 10] it was not identified as a risk factor in the present logistic regression analysis. >>> Also, there are many documents reporting that proton pump inhibitor use was NOT identified as risk factor of CDI.
4.
This finding might be influenced by the relatively high Helicobacter pylori infection rate in elderly Japanese people; proton pump inhibitors might produce smaller changes in pH levels in such patients than American and European patients.
[11] >>> This sentence should be deleted, since it is not scientific.
5.
The most salient limitation of the case-control study phase is the existence of many confounding factors In particular, probiotic use, which was recently shown to be correlated with CDI prevention, was not included in the predictive model of this study. >>> The most salient limitation of this study is the low number of registered CDI cases from quite a few participants.
Recently there are also documents reporting that probiotics do NOT prevent CDI, which should be referred. 6.
The last paragraph is long and gives nothing new. It should be shortened.
REVIEWER
Paul Ananth Tambyah National University of Singapore I have received support from Sanofi-Pasteur for an epidemiological study of a C.difficile as well as for a clinical trial of a vaccine REVIEW RETURNED 14-Jun-2014
GENERAL COMMENTS
This is an important manuscript because as the authors point out, there are no national data published in English on the epidemiology of C.difficile infection in Japan. There are however a number of concerns about the manuscript: 1) The definition of C.difficile infection is important -most studies use 3 or more loose stools rather than "any gastrointestinal symptoms". The reason for the alternative definition should be discussed 2) Table 1 lists two centers which do not use toxin assay but rather culture alone -this is not usual and should be justified too 3) The reason for fewer controls than cases should be explainedmost studies have more controls than cases 4) For the tables, it should be age <74, not age 74 5) The presentation of table 3 is not clear -it should be shown how many patients were on vancomyin alone among those who died and those who survived and compared with those on metronidazole. Then a comparison can be made between vancomycin and metronidazole 6) If patients were not asked about their participation and their data were just recorded, how did they have the right to refuse participation? That should be explained 7) Although the numbers were small, it would be interesting to know risk factors for mortality in a multivariable analysis 8) A number of Japanese reports (admittedly from single centers) Mainly published in the Journal of Infection and Chemotherapy should be referenced to place this epidemiology study in context.
This appears to be a case control study but it would be good to have a statistician explain why they have fewer controls and how they attempted to do a cohort analysis within the cases.
VERSION 1 -AUTHOR RESPONSE
Reviewer Name Haru Kato Institution and Country National Institute of Infectious Diseases, Japan Please state any competing interests or state "None declared": None declared This should be the first step of multicenter study of CDI in Japan, even if it has quite a few weak points and limitations. Of their results, it is interesting that the use of vancomycin was associated with a decreased risk of mortality. This study might show the actual situation that people in Japanese medical facilities need more education for awareness and understanding for CDI. I think that it might be good to discuss of it. The paper can be compacted. The authors need to refer more appropriate references. It is quite strange that authors did refer no publications documenting CDI in Japan.
This is an interesting study about Clostridium difficile infections in Japan, because fewer reports have been documented from Japan so far. The biggest limitation of the paper is that the incidence of CDI was not described. It is quite impressive that 16 of 47 (34%) facilities did register fewer than 10 CDI cases during the one-year study period; especially five of these had no CDI cases. The authors explained that the reason of it is poor understanding for CDI in these facilities even if they were involved in the project. The authors could discuss more about the situation in Japan that poor awareness and poor understanding might lead to low density of testing and low incidence of CDI. This point might be important information especially for Japanese people working in medical facilities. The authors said in the INTRODUCTION "Consequently, the phenomenon of CDI in Japan is not sufficiently understood", but I do not think the authors themselves could report sufficiently about the phenomenon of CDI in Japan in this study with data from facilities, some of which reported very low number of CDI cases.
⇒Thank you for reviewing our manuscript. We also recognized poor understanding for CDI in some Japanese doctors and facilities during the study period. We did not think that the Japanese CDI incidence could be described in this study design, however this first CDI investigation showed the real situation of Japanese medical facilities for CDI. We wish this report will be a first opportunity of good understanding and education for Japanese medical doctors and facilities.
Introduction 1. In this study, the authors did not represent the incidence of CDI in Japanese hospitals. The following sentences should be deleted: In Japan, the Ministry of Health, Welfare, and Labor"s Japan Nosocomial Infection Surveillance program investigates the incidence rates of a variety of drugresistant bacteria; however, this program does not monitor the incidence rate of C. difficile (http://www.nih-janis.jp/index.asp). ⇒We delete the sentences in lines 64-66 page 4.
2. Therefore, CDI epidemiological studies in Japan to date have been based on scattered data from individual medical facilities. >>> References reporting "scattered data from Japan" should be referred. It is strange that no papers about CDI in Japan were referred in this study. ⇒We refer the some reports from the single institution in Japan in line 68 page 4.
3. Consequently, the phenomenon of CDI in Japan is not sufficiently understood. Reports of BI/NAP1/027 infections are limited, and conditions in Japan possibly differ from those in Europe and North America. >>> Please give me good reasons why the authors did cite no papers about CDI or typing analysis from Japan. In this study, Clostridium difficile isolates recovered from the 47 facilities were not analyzed, and then the authors could give no data about CDI caused by BI/NAP1/027 or other types in Japan. The sentences might be changed. ⇒We did not analyze the types of Clostridium difficile in this study, and we could give no data about CDI caused by BI/NAP1/027 or other types in Japan as reviewer pointed out. The reports of Clostridium difficile from single facility and typing in Japan were referred in line 68 page 4. "Consequently, the phenomenon of CDI in Japan is not sufficiently understood. Reports of BI/NAP1/027 infections are limited, and conditions in Japan possibly differ from those in Europe and North America." in lines 67-69 page 4 was changed to "Consequently, the phenomenon of CDI in Japan is not sufficiently understood, including C.difficile typing."
Materials and Methods 1. Definition of CDI is poorly described. Does "C. difficile isolation from stool culture" mean toxigenic culture? Especially in two facilities, only C. difficile culture was used for the laboratory test (Table 1) . ⇒ The stool culture was not toxigenic culture. As this was a multi-institution study, definition of CDI had to be simple and we regarded clinical diagnosis as important in this study. We defined CDI as the presence of clinical symptoms and positive results of toxin test or stool culture. We add the sentence "Only C. difficile culture but not toxin test was used for the laboratory test in two facilities." in the discussion of limitation, in lines 268-269 page 18.
2. It should be clear that the control group cases were selected regardless of intestinal symptoms such as diarrhea. ⇒ The control group cases were selected regardless of intestinal symptoms such as diarrhea.
We add the sentence "The control group cases were selected regardless of gastrointestinal symptoms such as diarrhea." in line 114 page 6.
3. The following sentences might be deleted; The study coordinator established independent data management centers within the NHO facilities for data collection. All input data were verified by a designated study data manager. Data from each facility were entered directly into a web-based case report form and subsequently encrypted for security. The data management center was responsible for confirming any missing data and directly inquiring the relevant facilities as necessary. After the end of the study period, the data were finalized and subsequently transferred to the Research Coordinator"s office. ⇒ We delete and change the sentences "The study coordinator established independent data management centers within the NHO facilities for data collection. All input data were verified by a designated study data manager. Data from each facility were entered directly into a web-based case report form and subsequently encrypted for security. The data management center was responsible for confirming any missing data and directly inquiring the relevant facilities as necessary. After the end of the study period, the data were finalized and subsequently transferred to the Research Coordinator"s office." to "The study coordinator established independent data management centers within the NHO facilities for data collection. All input data were verified by a designated study data manager. Data from each facility were entered directly into a web-based case report form and subsequently encrypted for security. The data management center was responsible for confirming any missing data and directly inquiring the relevant facilities as necessary. After the end of the study period, the data were finalized and subsequently transferred to the Research Coordinator"s office." in lines 130 and 133-134 page 7.
4. In this study, clinical outcomes of cases within 30 days of CDI development were investigated. How did the authors investigate it? Did the authors make a phone call the all patients who discharged from the facilities without taking any direct informed consent when they were involved in the study? ⇒ Clinical outcomes of cases who discharged within 30 days of CDI development were not investigated in this study, We add the sentence "Clinical outcomes of patients who discharged within 30 days of CDI development were not investigated in this study." in lines 120-121 page 6-7.
Results 1. The following sentences might be deleted; the regional locations of the 47 facilities were as follows: 5 in Hokkaido and Tohoku, 10 in Kanto and Koshinetsu, 2 in Tokai and Hokuriku, 9 in Kinki, 10 in Chugoku and Shikoku, and 11 in Kyushu and Okinawa. ⇒ We delete the sentences in lines 158-159 page 8. We add the sentences "The recurrence rate was low (4.8%) in this study compared to the previous studies. [11, 26] We did not investigate the patients neither after 30 days of CDI development nor the patients who discharge even if within 30 days of CDI development. Therefore, the recurrence rate might be underestimated. " in lines 248-251 page 17.
2. The findings of this investigation are similar to those reported in previous studies conducted in Europe, North America, and Australia >>> The incidence of CDI differs from those reported form Europe, North America, and Australia. It could be mentioned that this point possibly may have an effect on risk factors or mortality. ⇒We change the sentence "The findings of this investigation are similar to those reported in previous studies conducted in Europe, North America, and Australia with respect to the identification of several risk factors for CDI development, including age, severity of the underlying condition, and artificial feeding." To "The findings of this investigation are similar to those reported in previous studies conducted in Europe, North America, and Australia with respect to the identification of several risk factors for CDI development, including age, severity of the underlying condition, artificial feeding and mortality." in lines 225-228 page 16.
3. Although proton pump inhibitor use was indicated as a risk factor for CDI development in previous studies[9, 10] it was not identified as a risk factor in the present logistic regression analysis. >>> Also, there are many documents reporting that proton pump inhibitor use was NOT identified as risk factor of CDI. ⇒We change the sentence "Although proton pump inhibitor use was indicated as a risk factor for CDI development in previous studies, it was not identified as a risk factor in the present logistic regression analysis" to "The proton pump inhibitor use was discussed as a risk factor for CDI development in the previous studies. In the present logistic regression analysis, it was not identified as a risk factor." in lines 231-232 page 16. We also refer the report that proton pump inhibitor use was not identified as risk factor in line 232 page 16.
4. This finding might be influenced by the relatively high Helicobacter pylori infection rate in elderly Japanese people; proton pump inhibitors might produce smaller changes in pH levels in such patients than American and European patients.
[11] >>> This sentence should be deleted, since it is not scientific. ⇒We delete the sentence in lines 232-234 page 16.
5. The most salient limitation of the case-control study phase is the existence of many confounding factors In particular, probiotic use, which was recently shown to be correlated with CDI prevention, was not included in the predictive model of this study. >>> The most salient limitation of this study is the low number of registered CDI cases from quite a few participants. Recently there are also documents reporting that probiotics do NOT prevent CDI, which should be referred. ⇒We add the sentence "The most salient limitation is the low number of registered CDI cases from quite a few participants." In lines 252-253 page 17. We change the sentence "The most salient limitation of the case-control study phase is the existence of many confounding factors." to "Another limitation of the case-control study phase is the existence of many confounding factors." in lines 253-254 page 17. We also change the sentence "In particular, probiotic use, which was recently shown to be correlated with CDI prevention, was not included in the predictive model of this study." to "In particular, probiotic use, which was recently discussed to be correlated with CDI prevention, was not included in the predictive model of this study." in lines 254-256 page 17 and we referred the report which probiotics do not prevent CDI. We also change the sentences "The most salient limitation of the case-control study phase is the existence of many confounding factors. In particular, probiotic use, which was recently shown to be correlated with CDI prevention, was not included in the predictive model of this study." to "The limitation of this study is the low number of registered CDI cases from quite a few participants and the existence of many confounding factors." in the strength and limitation of this study in lines 55-56 page 3.
6. The last paragraph is long and gives nothing new. It should be shortened. ⇒We delete some sentences in the last paragraph in lines 271-273 and 274-275 and 277 page 18.
Reviewer Name Paul Ananth Tambyah Institution and Country National University of Singapore Please state any competing interests or state "None declared": I have received support from Sanofi-Pasteur for an epidemiological study of a C.difficile as well as for a clinical trial of a vaccine This is an important manuscript because as the authors point out, there are no national data published in English on the epidemiology of C.difficile infection in Japan.
There are however a number of concerns about the manuscript: 1) The definition of C.difficile infection is important -most studies use 3 or more loose stools rather than "any gastrointestinal symptoms". The reason for the alternative definition should be discussed ⇒ As this was a multi-institution study, definition of CDI had to be simple and we regarded clinical diagnosis as important in this study. We defined CDI as the presence of clinical symptoms and positive results of toxin test or stool culture, however the times of diarrhea were not investigated.
We add "In the definition of CDI, the times of diarrhea were not investigated." in the discussion of limitation, in line 253 page 17.
2) Table 1 lists two centers which do not use toxin assay but rather culture alone -this is not usual and should be justified too ⇒ Although we educated the CDI diagnosis to each facility before the study start, it was difficult to enlighten in all 47 facilities. We add the sentence "Only C. difficile culture but not toxin test was used for the laboratory test in two facilities." in the discussion of limitation, in lines 268-269 page 18. Although we educated the CDI diagnosis to each facility before the study start, it was difficult to enlighten in all 47 facilities.
3) The reason for fewer controls than cases should be explained -most studies have more controls than cases ⇒We added "Concerning matching process, we tried to adopt 1 to 1 pair sampling matched with sex, age group and main diagnosis. Some hospital could not find appropriate control sample well matched with case sample. So total number of the control group was less than that of the case sample." to 259-262 lines 17 page.
4)
For the tables, it should be age <74, not age 74 ⇒We change "74 years old" and "85 years old" to "<=74" and ">=85" in Table 3 , 5) The presentation of table 3 is not clear -it should be shown how many patients were on vancomyin alone among those who died and those who survived and compared with those on metronidazole. Then a comparison can be made between vancomycin and metronidazole ⇒Compared to cases in which no anti-CDI drugs were administered, vancomycin administration yielded a significantly lowered risk of mortality in the CDI group, meanwhile no such lowered mortality was observed in cases treated with metronidazole in a logistic regression analysis. We add "alone" after Vancomycin and Metronidazole in table 3. We put the no anti-CDI drugs as a reference but not metronidazole in this multivariate analysis so that we could evaluate the efficacy of CDI treatment precisely.
6) If patients were not asked about their participation and their data were just recorded, how did they have the right to refuse participation? That should be explained ⇒The individual patients who met the inclusion criteria were not given direct informed consent, however information about the study was made public through postings on facility notice boards and webpages. Patients and their representative agents had the right to refuse study participation if they would like to. This study was conducted with the approval of the Central Ethics Committee of the NHO based on the "Ethical guidelines for epidemiological research" and "Ethical Guidelines for Clinical Research" of the Ministry of Health, Labour and Welfare.
7)
Although the numbers were small, it would be interesting to know risk factors for mortality in a multivariable analysis ⇒We appreciate reviewer"s good evaluation.
8) A number of Japanese reports (admittedly from single centers) Mainly published in the Journal of Infection and Chemotherapy should be referenced to place this epidemiology study in context ⇒We refer the report from the single institution in Japan in line 68 page 4.
This appears to be a case control study but it would be good to have a statistician explain why they have fewer controls and how they attempted to do a cohort analysis within the cases I am concerned about the conclusion. The majority of the patients were treated with vancomycin. About the same number who were treated with metronidazole were not treated at all. It is difficult to justify the conclusion that Vancomycin is superior to metronidazole or that it should be used for more severe cases. There was a possible association of vancomycin use with reduced mortality but there might have been other confounding variables which affected this finding. They have addressed most of the concerns raised in the first review but I am still a little concerned about the need to qualify the recommendation for vancomycin use from a diverse, heterogenous population without adequate numbers of controls I think that the major issue remaining for me is the one about recommending vancomycin with the possiblity of confounding.
⇒Thank you for reviewing our manuscript. We investigated the CDI treatment result with bivariate and multivariate logistic regression analysis, which could concern the confounding factors, however we may not retrieve all confounding factors.
We think the vancomycin superiority should be understood with the influence of remaining confounding factors.
As the reviewer pointed out, we do not compare the mortality rate of vancomycin and metronidazole directly but we selected the no treatment as a reference and investigated the vancomycin and metronidazole treatment effect compared to the no treatment reference in our cohort study. We think that our results showed use of vancomycin was associated with reduced risk of mortality whereas metronidazole was not, however we could not show the superior effect of vancomycin directly compared to metronidazole. We changed the sentence, "the use of vancomycin rather than metronidazole for treatment appears to have provided better outcomes." to "the use of vancomycin expected to reduce the mortality." in lines 239-240 page 17.
